Treatment with cabozantinib, an inhibitor of MET and VEGFR2 signaling, has demonstrated clinical benefit in early trials in men with metastatic prostate cancer.
Preclinical evidence suggests that cabozantinib can kill cancer cell seeds while disrupting angiogenesis and stromal cells in the metastatic soil.
Written by:
Lee RJ, Smith MR. Are you the author?
Massachusetts General Hospital Cancer Center, Harvard Medical School.
Reference: Clin Cancer Res. 2013 Nov 27. Epub ahead of print.
doi: 10.1158/1078-0432.CCR-13-2636
PubMed Abstract
PMID: 24284057
UroToday.com mCRPC Treatment Section
